Literature DB >> 8376701

Factors contributing to the exercise limitation of heart failure.

J R Wilson1, D M Mancini.   

Abstract

Exertional intolerance is a major clinical problem in ambulatory patients with chronic heart failure and is associated with both muscle fatigue and dyspnea. The increased muscle fatigability is most likely caused by a combination of muscle underperfusion and muscle deconditioning; patients frequently exhibit skeletal muscle atrophy, altered muscle metabolism and reduced mitochondrial-based enzyme levels, consistent with deconditioning. The muscle underperfusion is largely due to impaired arteriolar vasodilation within exercising muscle. Exertional dyspnea appears to be due to increased respiratory muscle work mediated by excessive ventilation and decreased lung compliance. Both excessive carbon dioxide production, secondary to increased muscle lactate release, and increased lung dead space contribute to the excessive ventilation. Decreased lung compliance is caused by chronic pulmonary congestion and fibrosis. Optimal management of exercise intolerance in patients with heart failure requires an understanding of the role of these multiple potential contributors to exertional fatigue and dyspnea.

Entities:  

Mesh:

Year:  1993        PMID: 8376701     DOI: 10.1016/0735-1097(93)90469-h

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  27 in total

1.  Chronic heart failure decreases cross-bridge kinetics in single skeletal muscle fibres from humans.

Authors:  Mark S Miller; Peter VanBuren; Martin M LeWinter; Joan M Braddock; Philip A Ades; David W Maughan; Bradley M Palmer; Michael J Toth
Journal:  J Physiol       Date:  2010-08-19       Impact factor: 5.182

2.  Interstitial K+ concentration in active muscle after myocardial infarction.

Authors:  Jianhua Li; Zhaohui Gao; Valerie Kehoe; Lawrence I Sinoway
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-09-29       Impact factor: 4.733

3.  Influence of the metaboreflex on arterial blood pressure in heart failure patients.

Authors:  Manda L Keller-Ross; Bruce D Johnson; Michael J Joyner; Thomas P Olson
Journal:  Am Heart J       Date:  2014-01-06       Impact factor: 4.749

4.  Oxidative stress and the muscle reflex in heart failure.

Authors:  Satoshi Koba; Zhaohui Gao; Lawrence I Sinoway
Journal:  J Physiol       Date:  2009-09-01       Impact factor: 5.182

Review 5.  Neuroendocrine changes in chronic cardiac failure.

Authors:  D P Nicholls; G N Onuoha; G McDowell; J S Elborn; M S Riley; A M Nugent; I C Steele; C Shaw; K D Buchanan
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

6.  Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure.

Authors:  Guangqiu Feng; Yu Yang; Juan Chen; Zhiyong Wu; Yin Zheng; Wei Li; Wenxin Dai; Pin Guan; Chunrong Zhong
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 7.  Resistance versus aerobic exercise training in chronic heart failure.

Authors:  Sandra Mandic; Jonathan Myers; Steve E Selig; Itamar Levinger
Journal:  Curr Heart Fail Rep       Date:  2012-03

8.  Analysis of Skeletal Muscle Torque Capacity and Circulating Ceramides in Patients with Advanced Heart Failure.

Authors:  Danielle L Brunjes; Mark Dunlop; Christina Wu; Meaghan Jones; Tomoko S Kato; Peter J Kennel; Hilary F Armstrong; Tse-Hwei Choo; Matthew N Bartels; Daniel E Forman; Donna M Mancini; P Christian Schulze
Journal:  J Card Fail       Date:  2016-02-12       Impact factor: 5.712

9.  Skeletal muscle contractile protein function is preserved in human heart failure.

Authors:  Yoko Okada; Michael J Toth; Peter Vanburen
Journal:  J Appl Physiol (1985)       Date:  2008-01-17

10.  Contribution of nerve growth factor to augmented TRPV1 responses of muscle sensory neurons by femoral artery occlusion.

Authors:  Jihong Xing; Jian Lu; Jianhua Li
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.